174 related articles for article (PubMed ID: 37016335)
1. Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling.
Gao J; Hu J; Yu F; Wang C; Sheng D; Liu W; Hu A; Yu K; Xiao X; Kuang Y; Zacksenhaus E; Gajendran B; Ben-David Y
BMC Cancer; 2023 Apr; 23(1):306. PubMed ID: 37016335
[TBL] [Abstract][Full Text] [Related]
2. ERK activation via A1542/3 limonoids attenuates erythroleukemia through transcriptional stimulation of cholesterol biosynthesis genes.
Yu F; Gajendran B; Wang N; Sample KM; Liu W; Wang C; Hu A; Zacksenhaus E; Hao X; Ben-David Y
BMC Cancer; 2021 Jun; 21(1):680. PubMed ID: 34107900
[TBL] [Abstract][Full Text] [Related]
3. UM171 cooperates with PIM1 inhibitors to restrict HSC expansion markers and suppress leukemia progression.
Hu A; Gao J; Varier KM; Gajendran B; Jiang F; Liu W; Wang C; Xiao X; Li Y; Zacksenhaus E; Ali S; Ben-David Y
Cell Death Discov; 2022 Nov; 8(1):448. PubMed ID: 36335089
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin counteracts high glucose-induced Krüppel-like factor 2 suppression in human umbilical vein endothelial cells.
Liu YS; Xu DL; Huang ZW; Hao L; Wang X; Lu QH
Postgrad Med; 2015 Jun; 127(5):446-54. PubMed ID: 25927862
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.
Dimitroulakos J; Ye LY; Benzaquen M; Moore MJ; Kamel-Reid S; Freedman MH; Yeger H; Penn LZ
Clin Cancer Res; 2001 Jan; 7(1):158-67. PubMed ID: 11205904
[TBL] [Abstract][Full Text] [Related]
6. Proliferation of rabbit chondrocyte and inhibition of IL-1β-induced apoptosis through MEK/ERK signaling by statins.
Zhou B; Chen D; Xu H; Zhang X
In Vitro Cell Dev Biol Anim; 2017 Feb; 53(2):124-131. PubMed ID: 27709418
[TBL] [Abstract][Full Text] [Related]
7. Lovastatin sensitizes lung cancer cells to ionizing radiation: modulation of molecular pathways of radioresistance and tumor suppression.
Sanli T; Liu C; Rashid A; Hopmans SN; Tsiani E; Schultz C; Farrell T; Singh G; Wright J; Tsakiridis T
J Thorac Oncol; 2011 Mar; 6(3):439-50. PubMed ID: 21258249
[TBL] [Abstract][Full Text] [Related]
8. Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase.
Johnson MD; Woodard A; Okediji EJ; Toms SA; Allen GS
J Neurooncol; 2002 Jan; 56(2):133-42. PubMed ID: 11995814
[TBL] [Abstract][Full Text] [Related]
9. Cell-cycle gene expression in lovastatin-induced medulloblastoma apoptosis.
Wang W; Macaulay RJ
Can J Neurol Sci; 2003 Nov; 30(4):349-57. PubMed ID: 14672267
[TBL] [Abstract][Full Text] [Related]
10. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins.
Marrone G; Russo L; Rosado E; Hide D; García-Cardeña G; García-Pagán JC; Bosch J; Gracia-Sancho J
J Hepatol; 2013 Jan; 58(1):98-103. PubMed ID: 22989565
[TBL] [Abstract][Full Text] [Related]
11. Differentiation and apoptosis induction by lovastatin and γ-tocotrienol in HL-60 cells via Ras/ERK/NF-κB and Ras/Akt/NF-κB signaling dependent down-regulation of glyoxalase 1 and HMG-CoA reductase.
Chen CC; Liu TY; Huang SP; Ho CT; Huang TC
Cell Signal; 2015 Nov; 27(11):2182-90. PubMed ID: 26208883
[TBL] [Abstract][Full Text] [Related]
12. Selective ERK1/2 agonists isolated from Melia azedarach with potent anti-leukemic activity.
Wang N; Fan Y; Yuan CM; Song J; Yao Y; Liu W; Gajendran B; Zacksenhaus E; Li Y; Liu J; Hao XJ; Ben-David Y
BMC Cancer; 2019 Aug; 19(1):764. PubMed ID: 31375085
[TBL] [Abstract][Full Text] [Related]
13. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis.
Wu J; Wong WW; Khosravi F; Minden MD; Penn LZ
Cancer Res; 2004 Sep; 64(18):6461-8. PubMed ID: 15374955
[TBL] [Abstract][Full Text] [Related]
14. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach.
Dimitroulakos J; Nohynek D; Backway KL; Hedley DW; Yeger H; Freedman MH; Minden MD; Penn LZ
Blood; 1999 Feb; 93(4):1308-18. PubMed ID: 9949174
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic levels of the hydroxmethylglutaryl-coenzyme A reductase inhibitor lovastatin activate ras signaling via phospholipase D2.
Cho KJ; Hill MM; Chigurupati S; Du G; Parton RG; Hancock JF
Mol Cell Biol; 2011 Mar; 31(6):1110-20. PubMed ID: 21245384
[TBL] [Abstract][Full Text] [Related]
16. Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells.
Bassa BV; Roh DD; Vaziri ND; Kirschenbaum MA; Kamanna VS
Biochim Biophys Acta; 1999 Mar; 1449(2):137-49. PubMed ID: 10082972
[TBL] [Abstract][Full Text] [Related]
17. HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway.
Laezza C; Mazziotti G; Fiorentino L; Gazzerro P; Portella G; Gerbasio D; Carella C; Matarese G; Bifulco M
J Mol Med (Berl); 2006 Nov; 84(11):967-73. PubMed ID: 16947002
[TBL] [Abstract][Full Text] [Related]
18. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth.
Moriceau G; Roelofs AJ; Brion R; Redini F; Ebetion FH; Rogers MJ; Heymann D
Cancer; 2012 Feb; 118(3):750-60. PubMed ID: 21751201
[TBL] [Abstract][Full Text] [Related]
19. Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer.
Kaneko R; Tsuji N; Asanuma K; Tanabe H; Kobayashi D; Watanabe N
J Biol Chem; 2007 Jul; 282(27):19273-81. PubMed ID: 17472962
[TBL] [Abstract][Full Text] [Related]
20. Mevalonate prevents lovastatin-induced apoptosis in medulloblastoma cell lines.
Wang W; Macaulay RJ
Can J Neurol Sci; 1999 Nov; 26(4):305-10. PubMed ID: 10563217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
